without changing your settings we'll assume you are happy to receive all RSC cookies.
You can change your cookie settings by navigating to our Privacy and Cookies page and following the instructions. These instructions
are also obtainable from the privacy link at the bottom of any RSC page.
Oligosaccharide-modified poly(propylene imine) dendrimers are promising candidates as drug carriers and as anti-prion agents. Here, we report the biodistribution of maltotriose-modified 4th generation poly(propylene imine) (PPI) dendrimers and their ability to cross the blood–brain–barrier that is important if these glycodendrimers are considered as potential therapeutic agents in the central nervous system (CNS).
Fetching data from CrossRef. This may take some time to load.